<DOC>
	<DOCNO>NCT00666133</DOCNO>
	<brief_summary>Preeclampsia condition unique pregnancy characterize new onset hypertension proteinuria . Eclampsia , characterize maternal seizure , serious complication increase risk maternal infant mortality morbidity . Magnesium sulfate drug choice prevention treat convulsion severe preeclampsia eclampsia . Magnesium sulfate administer parenterally intramuscular ( IM ) intravenous route ( IV ) . In general loading dose 4 5 gram magnesium sulfate administer intravenously follow IM injection every 4 hour continuous IV infusion . The IV regimen achieve stable serum level magnesium require use infusion pump safe delivery great potential inadvertent overdose . Although magnesium sulfate demonstrate safe effective drug treatment prevention severe preeclampsia eclampsia , concern safety drug remain . The IM dose regimen , potentially safe , require repeat painful IM injection . These limitation administration hinder widespread use magnesium sulfate despite demonstrated benefit . The goal research develop system care avoids overdose facilitates use magnesium sulfate treatment preeclampsia . To end , primary objective research demonstrate safety simple , inexpensive flow control pump system ( Springfusor® ) . This randomized study compare administration magnesium sulfate Springfusor® control pump IM regimen , standard care hospital India . The study document efficacy acceptability treatment patient staff compare cost time element involve provide method .</brief_summary>
	<brief_title>Treatment Approaches Preeclampsia Low-Resource Settings</brief_title>
	<detailed_description />
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>Exhibit systolic blood pressure &gt; 140mm Hg OR diastolic pressure &gt; 100 mm Hg ; Exhibit proteinuria &gt; 1+ ; Have give birth , 24h less postpartum ; Exhibit urine output &gt; 100 ml previous 4h great 25 mL/h ; Agree comply study procedure ; Be &gt; 18 year age ; Give inform consent study participation Eclamptic seizing time enrollment Received magnesium sulfate therapy 24h prior study enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Preeclampsia</keyword>
	<keyword>Eclampsia</keyword>
	<keyword>Magnesium Sulfate</keyword>
</DOC>